Iantrek Expands Clinical Evidence for Bio-Interventional Ophthalmic Surgery Across Trabecular and Uveoscleral Outflow Pathways

Iantrek, News

Iantrek, Inc., a company pioneering bio-interventional ophthalmic surgery (BIOS), today announced topline six-month results from a first-in-human, investigator-initiated study evaluating bio-reinforced canaloplasty targeting the trabecular outflow pathway. At six months, mean intraocular pressure (IOP) decreased by 37.2% from a baseline of 22.4 mmHg, with 90% of eyes achieving an IOP of 18 mmHg or lower. Mean glaucoma medication use also decreased by 49.1% from a baseline of 1.2 medications.

Pelage Pharmaceuticals grabbed spot number 9 in Fierce Biotech’s 2026 Fierce 15

News, Pelage

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the close of a $120 million Series B financing co-led by ARCH Venture Partners and GV (Google Ventures), with participation from existing investors including Main Street Advisors, Visionary Ventures, and YK Bioventures. The financing will support the continued advancement of Pelage’s lead program, PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.